At the recent PDA Universe of Prefilled Syringes and Injection Devices conference in Phoenix Arizona, there were many conversations about the manufacturing landscape for drug delivery devices. The demand for weight management drugs, such as GLP-1s, has put immense pressure on manufacturing capacity.[1] The shortage of available manufacturing capacity threatens to delay product launches and limit access for all injectable medicines as more pharmaceutical companies race to launch new drugs and devices for patients.
The manufacturing strain is exacerbated by the resource-intensive nature of scaling up the fill-finish of primary drug containers, and the manufacture of drug delivery devices, which often require specialized machinery, regulatory compliance, and rigorous quality control. The acquisition of Catalent by Novo Holdings for $16.5B in February 2024 demonstrates the value placed on manufacturing capacity.[2]
Sanner Group: Bridging the capacity gap
Sanner has recognized the urgent need for adaptable, scalable production. We have invested in new manufacturing facilities in North America, Europe, and China, that are capable of handling high-volume manufacturing for pharmaceutical and medical device customers. This includes a commitment to quality at each stage of production, from component sourcing to final assembly. For pharmaceutical executives, partnering with a manufacturer like Sanner ensures a pathway to scale that prioritizes both quality and speed. With demand for manufacturing capacity at an all-time high, working with an experienced partner allows companies to mitigate the risks of production delays and quality lapses—two critical threats to market readiness.
As capacity becomes a differentiating factor in the pharmaceutical industry, pharmaceutical executives must shift their focus from a pure innovation-based approach to one that balances innovation with pragmatic production capabilities. The journey to market requires aligning with partners that can provide the necessary capacity, maintain rigorous quality standards, and prioritize user-friendly designs that resonate with patients and healthcare providers alike.
Sanner Group exemplifies this holistic approach to pharmaceutical manufacturing, offering customers the support they need to navigate a constrained capacity landscape. By integrating patient-centric device design with agile, scalable, reliable, high-volume manufacturing capabilities, pharmaceutical companies can ensure their products are not only market-ready but also competitive in an increasingly complex market.
Contact us today to find out how we can help.
[1] J.P. Morgan doubles GLP-1 market projection to $71B in 2032.
[2] Novo Holdings to Acquire Catalent | Catalent Pharma Solutions
